Preclinical trials of ganglioside 2 (GD2), protein tyrosine kinase 7 (PTK7), and NKG2DL as CAR-T cell therapy targets also showed anti-BC activity [177, 193–195] (Fig. 3). This evidence concerns the gene PTK7 and breast cancer.